Literature DB >> 16966732

Managing biotechnology in a network-model health plan: a U.S. private payer perspective.

John B Watkins1, Sanchita Roy Choudhury, Ed Wong, Sean D Sullivan.   

Abstract

Emerging biotechnology poses challenges to payers, including access, coverage, reimbursement, patient selection, and affordability. Premera Blue Cross, a private regional health plan, developed an integrated cross-functional approach to managing biologics, built around a robust formulary process that is fast, flexible, fair, and transparent to stakeholders. Results are monitored by cost and use reporting from merged pharmacy and medical claims. Utilization management and case management strategies will integrate with specialty pharmacy programs to improve outcomes and cost-effectiveness. Creative approaches to provider reimbursement can align providers' incentives with those of the plan. Redesign of member benefits can also encourage appropriate use of biotechnology.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16966732     DOI: 10.1377/hlthaff.25.5.1347

Source DB:  PubMed          Journal:  Health Aff (Millwood)        ISSN: 0278-2715            Impact factor:   6.301


  1 in total

Review 1.  Economic evaluation in the US: what is the missing link?

Authors:  Peter J Neumann; Sean D Sullivan
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.